Precision Medicine Group (PMG) has acquired Project Farma, a bioengineering services firm that supports the manufacture and scale-up of advanced therapies. Project Farma provides Precision in the manufacture of advanced medicines, with a unique focus in the rapidly growing area of cell and gene therapy. The acquisition adds Project Farma’s unique expertise to Precision’s suite of end-to-end cell and gene therapy capabilities to support development and commercialization.
 
Project Farma has led more than a dozen manufacturing facility builds with capital investments greater than $1 billion (including some of the leading FDA-approved cell and gene therapy medicines). Project Farma will be part of Precision for Medicine, PMG’s research and development services arm.
 
Mark Clein, CEO of Precision Medicine Group, said, “Since 2013, Precision has supported over 70% of the FDA- approved cell and gene therapies and is now even better positioned to support the hundreds of therapeutic new entrants coming to market.  With our acquisition of Project Farma, Precision is the only life-science services company with true end-to-end capabilities in cell and gene therapy.”
 
Anshul Mangal shared, “We are excited to join Precision’s cell and gene therapy collective, leveraging interconnected services to accelerate the development, manufacturing, and commercialization of advanced therapies.” Added Tony Khoury, “We realize Precision ADVANCE presents an unbelievable opportunity to further next generation medicines and to further Project Farma’s and Precision’s shared mission to positively impact as many patients and families as possible.”